Erna Domsgen

Chief Executive Officer (CEO)

Therapeutic Areas

Drug	Indication	Phase
SPOT-it™ SCID	Severe Combined Immunodeficiency (SCID) Newborn Screening	Approved
SPOT-it™ SCID XLA	SCID and X-linked Agammaglobulinemia (XLA) Newborn Screening	Approved
SPOT-it™ SCID SMA	SCID and Spinal Muscular Atrophy (SMA) Newborn Screening	Approved
SPOT-it™ SCID SMA XLA	SCID, SMA, and XLA Newborn Screening	Approved